Compare · FOLD vs NVO
FOLD vs NVO
Side-by-side comparison of Amicus Therapeutics Inc. (FOLD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FOLD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $203.51B, about 44.7x FOLD ($4.55B).
- Over the past year, FOLD is up 135.3% and NVO is down 37.4% - FOLD leads by 172.7 points.
- NVO has been more active in the news (10 items in the past 4 weeks vs 2 for FOLD).
- NVO has more recent analyst coverage (25 ratings vs 20 for FOLD).
- Company
- Amicus Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $14.49+0.21%
- $45.60+0.22%
- Market cap
- $4.55B
- $203.51B
- 1M return
- +0.52%
- +13.21%
- 1Y return
- +135.31%
- -37.38%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2007
- News (4w)
- 2
- 10
- Recent ratings
- 20
- 25
Amicus Therapeutics Inc.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest FOLD
- SEC Form SCHEDULE 13G filed by Amicus Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Amicus Therapeutics Inc.
- SEC Form 15-12G filed by Amicus Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Amicus Therapeutics Inc.
- SEC Form EFFECT filed by Amicus Therapeutics Inc.
- SEC Form EFFECT filed by Amicus Therapeutics Inc.
- SEC Form EFFECT filed by Amicus Therapeutics Inc.
- SEC Form EFFECT filed by Amicus Therapeutics Inc.
- SEC Form EFFECT filed by Amicus Therapeutics Inc.
- SEC Form EFFECT filed by Amicus Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
- The Next Generation of the GLP-1 Revolution Is Already Underway